FibroGen (NASDAQ:FGEN) Posts Quarterly Earnings Results

FibroGen (NASDAQ:FGEN) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06, Zacks reports.

FibroGen Stock Up 1.3 %

FibroGen stock traded up $0.01 during midday trading on Monday, reaching $0.45. The stock had a trading volume of 1,363,100 shares, compared to its average volume of 2,320,345. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.80. The firm has a market cap of $44.84 million, a price-to-earnings ratio of -0.36 and a beta of 0.82. The company has a fifty day moving average of $0.51 and a 200 day moving average of $0.43.

Analyst Ratings Changes

FGEN has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of FibroGen in a report on Thursday, February 20th. StockNews.com began coverage on shares of FibroGen in a research report on Friday. They set a “hold” rating on the stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.